Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed Price. Currency in USD
29.27+0.05 (+0.15%)
At close: 3:59 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close29.23
Bid0.00 x
Ask0.00 x
Day's Range29.14 - 29.28
52wk Range29.14 - 35.13
1y Target EstN/A
Market Cap204.58B
P/E Ratio (ttm)21.98
Avg Vol (3m)994,285
Dividend & Yield1.02 (3.48%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire2 hours ago

    LabCorp is first US laboratory to offer molecular testing with new fully automated cobas 8800 system from Roche

    OTCQX: RHHBY) and Laboratory Corporation of America® Holdings (LabCorp®) (LH) announced today that the LabCorp Center for Esoteric Testing in Burlington, N.C., is the first site in the United States to offer commercial testing services with Roche's new cobas® 8800 system. The system automates the entire molecular diagnostics testing process—from specimen preparation and nucleic acid extraction/purification through polymerase chain reaction (PCR) amplification and detection—and is the first high-throughput molecular system to be approved by the FDA for CLIA moderately complex testing. LabCorp, the world's leading healthcare diagnostics company, is initially running hepatitis C viral load testing on the system and plans to add testing for HIV and hepatitis B virus in the coming months.

  • PR Newswire3 days ago

    Roche receives FDA approval for fully automated blood screening assay on the cobas® 6800/8800 Systems

    OTCQX: RHHBY) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the cobas® MPX test for use on the cobas® 6800 and 8800 Systems. The cobas® MPX test enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood and plasma in the United States, preventing the spread of Human Immunodeficiency Virus Groups 1 and 2 (HIV-1 and HIV-2), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) through transfused blood products. "This approval reinforces our strong presence in donor screening, and underscores our ability to provide proven, robust technology for the testing of donated blood and blood products," said Uwe Oberlaender, Head of Roche Molecular Diagnostics.

  • Roche (RHHBY) Misses Q3 Sales Estimates, 2016 View Intact
    Zacks3 days ago

    Roche (RHHBY) Misses Q3 Sales Estimates, 2016 View Intact

    Roche's (RHHBY) third-quarter 2016 sales missed the Zacks Consensus Estimate marginally.